ZHAOKE OPHTH expects multiple product applications to be approved in the second half of the year, hoping to expand its international network to Latin America or South America this year

ZHAOKE OPHTH-B (06622.HK) Chairman of the Board, Executive Director, and CEO Li Xiaoyi expects that multiple product applications under the group will be approved successively in the second half of the year.

Among them, Li Xiaoyi stated that the National Medical Products Administration accepted the new drug application for cyclosporine eye gel last May and received FDA approval for the new drug trial application in June last year. Atropine sulfate eye drops (NVK002) are currently undergoing regulatory review for market approval. The intravitreal injection of bevacizumab (TAB014) for the treatment of wet age-related macular degeneration has submitted a biopharmaceutical license application in China and is expected to be approved within this year, at which point it is anticipated to enter the national medical insurance drug list.

He also revealed that the group has established a legally compliant internet hospital in Nansha, Guangzhou, primarily for patient management.

Regarding overseas markets, he pointed out that the group covered Southeast Asia, the Middle East, South Korea, and Europe last year, and this year hopes to expand its international network to Latin America or South America, currently actively seeking opportunities in Brazil. He mentioned that based on the current R&D progress of Zhaoke's various drugs, including the FDA approval obtained earlier this year for the innovative drug Brimochol PF for presbyopia by Zhaoke's strategic partner, it is estimated that Zhaoke's overseas business could record revenue as early as 2028. In the long term, Zhaoke aims for overseas and domestic revenue to each account for half.

Regarding Zhaoke Ophthalmology's recently announced annual results, the loss narrowed from RMB 237 million in the previous year to RMB 209 million. The group's Vice President of Finance and Company Secretary Qiu Shuxin expects that with more products approved for market launch next year, the drug portfolio will become more diversified, coupled with the company's relatively conservative administrative expenses, it is anticipated that losses will gradually narrow.

She mentioned that the company will cautiously invest in R&D expenses going forward, and if the group's products can be launched in the market as scheduled, it is believed that cash outflow will significantly decrease